AAM Blasts Build Back Better But Bernstein Offers Balance

Discounted Drugs Could Disincentivize US Biosimilar Competition, Says AAM

 
• By Chloe Kent

Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.

Joe Biden stands in front of a Build Back Better poster
Build Back Better's proposed price controls could have a negative affect on the biosimilars industry • Source: Alamy

More from Policy & Regulation

More from Generics Bulletin